Position in HALO
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$584,836
+$376,139 QoQ
Shares Held
9,049
+191.8% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Gibbs Wealth Management holds $8,039,627 across 8 Biotechnology names. HALO ranks #6 (7.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,647 | $2,521,611 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,306 | $1,781,707 | |
| 3 | LGND |
Ligand Pharmaceuticals Inc
|
5,563 | $1,110,652 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
28,018 | $930,757 | |
| 5 | VCEL |
Vericel Corp
|
20,506 | $659,678 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
This page
|
9,049 | $584,836 | |
| 7 | TECH |
BIO-TECHNE Corp
|
8,131 | $424,926 | |
| 8 | EDIT |
Editas Medicine, Inc.
|
10,308 | $25,460 |
All Filings in HALO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $584,836 | 9,049 | Shares | Other | 2026-05-13 | |
| 2025-12-31 | $208,697 | 3,101 | Shares | Other | 2026-01-23 | |
| 2025-09-30 | $227,940 | 3,108 | Shares | Other | 2025-10-30 | |
| 2025-06-30 | $221,813 | 4,264 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $224,802 | 3,523 | Shares | Other | 2025-11-04 | |
| No filing history on record for this holder in this stock. | ||||||